FIELD: medicine, pharmacy.
SUBSTANCE: invention relates to a solid oral dosed sustained-release composition with film envelope used in treatment of patients with symptoms of allergic and/or inflammatory states. The composition comprises: (a) a core containing the effective amount of pseudoephedrine or its pharmaceutically acceptable salt, and (b) film envelope covering a core uniformly and comprising: (c) the second film envelope covering a film envelope (b) uniformly and containing the effective amount of desloratadine and wherein the amount of pseudoephedrine or its pharmaceutically acceptable salt is sufficient for providing the maximal average geometric values of plasma pseudoephedrine concentrations equal to from about 345 to about 365 ng/ml for time from about 7.60 to about 8.4 h, and wherein the amount of desloratadine is sufficient for providing the maximal average geometric concentrations of plasma desloratadine equal from about 2.10 to about 2.45 ng/ml for time from about 4.0 to about 4.5 h after dosing a single dose given in the composition.
EFFECT: improved and valuable medicinal and pharmaceutical properties of composition.
14 cl, 4 tbl, 4 ex
